Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,293,360
  • Shares Outstanding, K 1,275,510
  • Annual Sales, $ 22,127 M
  • Annual Income, $ 5,455 M
  • 60-Month Beta 1.16
  • Price/Sales 3.65
  • Price/Cash Flow 8.63
  • Price/Book 3.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.51
  • Number of Estimates 7
  • High Estimate 1.59
  • Low Estimate 1.32
  • Prior Year 1.37
  • Growth Rate Est. (year over year) +10.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.56 +2.27%
on 04/18/19
68.07 -7.52%
on 04/05/19
-2.07 (-3.18%)
since 03/18/19
3-Month
61.56 +2.27%
on 04/18/19
70.50 -10.71%
on 02/01/19
-6.23 (-9.01%)
since 01/18/19
52-Week
60.32 +4.36%
on 12/26/18
79.61 -20.93%
on 10/03/18
-12.73 (-16.82%)
since 04/18/18

Most Recent Stories

More News
Mass Tort Alleges Gilead Sciences, Inc. Withheld Safer Drugs From HIV/AIDS Patients, Manipulated Patent Timing for Profit, Announces Jenner Law

Eight patients who took the popular HIV/AIDS drug Truvada and similar tenofovir-based drugs have sued Gilead Sciences, Inc., claiming the giant pharmaceutical company deliberately withheld a much safer...

GILD : 62.95 (-0.47%)
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time,...

GILD : 62.95 (-0.47%)
Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology,...

PRNB : 29.64 (+2.17%)
HZNP : 24.92 (+1.30%)
GILD : 62.95 (-0.47%)
Can Q1 Earnings Lift Healthcare ETFs Higher?

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
MRK : 73.19 (-0.99%)
IYH : 181.00 (+0.17%)
FHLC : 41.65 (+0.14%)
ABBV : 77.57 (-0.53%)
GILD : 62.95 (-0.47%)
AMGN : 177.47 (-2.74%)
PFE : 39.38 (-1.25%)
UNH : 221.75 (+2.26%)
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

NVO : 48.39 (-0.25%)
MRK : 73.19 (-0.99%)
LLY : 115.20 (-1.12%)
GILD : 62.95 (-0.47%)
Can Q1 Earnings Lift Healthcare ETFs Higher?

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
MRK : 73.19 (-0.99%)
IYH : 181.00 (+0.17%)
FHLC : 41.65 (+0.14%)
ABBV : 77.57 (-0.53%)
GILD : 62.95 (-0.47%)
AMGN : 177.47 (-2.74%)
PFE : 39.38 (-1.25%)
UNH : 221.75 (+2.26%)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 2.11%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $63.18 to a high of $64.54. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $64.50...

GILD : 62.95 (-0.47%)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 2.11% Loss

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $63.18 to a high of $64.54. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $64.50...

GILD : 62.95 (-0.47%)
Gilead Collaborates With Insitro to Develop NASH Therapies

Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

NVO : 48.39 (-0.25%)
MRK : 73.19 (-0.99%)
AGN : 140.31 (+0.20%)
GILD : 62.95 (-0.47%)
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

CELG : 93.76 (-0.57%)
NVO : 48.39 (-0.25%)
VRTX : 168.16 (+0.71%)
GILD : 62.95 (-0.47%)
FCSC : 2.24 (-0.88%)
BMY : 45.52 (-0.61%)
AXSM : 15.01 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 64.76
1st Resistance Point 63.85
Last Price 62.95
1st Support Level 61.80
2nd Support Level 60.65

See More

52-Week High 79.61
Fibonacci 61.8% 72.24
Fibonacci 50% 69.96
Fibonacci 38.2% 67.69
Last Price 62.95
52-Week Low 60.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar